This segment focuses on the research, development, and commercialization of novel therapies for rare liver diseases, including progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Research and development activities include clinical trials for LIVMARLI (maralixibat) and Volixibat. Technologies and methodologies include small molecule drug development and clinical trial management. The segment addresses the unmet medical needs of patients suffering from these debilitating conditions, aiming to improve liver function, reduce symptoms like pruritus (itching), and enhance overall quality of life. Mirum's market positioning is as a leader in rare liver disease treatments, with a competitive advantage in its late-stage pipeline and focus on orphan drug development. Future opportunities include expanding the label for LIVMARLI and developing new therapies for other rare liver diseases. Regulatory and clinical aspects involve navigating FDA approval processes and conducting Phase 2 and 3 clinical trials. Partnerships and collaborations are crucial for commercialization and include agreements with companies like Abacus Medicine Pharma Services for commercialization of LIVMARLI in Nordic markets.